


Status: Currently Official on 17-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-4A9200C8-C456-4486-A155-51E266B6C0C1\_4\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M1324\\_04\\_01](https://doi.org/10.31003/USPNF_M1324_04_01)  
 DOI Ref: qpe3y

© 2025 USPC  
 Do not distribute

## Alendronate Sodium



$C_4H_{12}NNaO_7P_2 \cdot 3H_2O$

325.12

Phosphonic acid, (4-amino-1-hydroxybutylidene) bis-, monosodium salt, trihydrate;

Sodium trihydrogen (4-amino-1-hydroxybutylidene)diphosphonate, trihydrate CAS RN®: 121268-17-5; UNII: 2UY4M2U3RA.

### DEFINITION

Alendronate Sodium contains NLT 98.0% and NMT 102.0% of alendronate sodium ( $C_4H_{12}NNaO_7P_2$ ), calculated on the dried basis.

### IDENTIFICATION

**Change to read:**

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197M](#) ▲ (CN 1-MAY-2020)
- **B.** [IDENTIFICATION TESTS—GENERAL \(191\)](#), [Sodium](#): Meets the requirements of test A

### ASSAY

#### • PROCEDURE

**Buffer solution:** 14.7 g/L of sodium citrate dihydrate and 7.05 g/L of anhydrous dibasic sodium phosphate. Adjust with phosphoric acid to a pH of 8.

**Mobile phase:** Acetonitrile, methanol, and *Buffer solution* (25:5:70)

**Diluent:** 29.4 g/L of sodium citrate dihydrate

**Borate solution:** 19.1 g/L of sodium borate

**Solution A:** 0.5 mg/mL of 9-fluorenylmethyl chloroformate in acetonitrile. [NOTE—Prepare this solution fresh just before use.]

**Standard stock solution:** 0.1 mg/mL of [USP Alendronate Sodium RS](#) in *Diluent*

**Standard solution:** Transfer 5.0 mL of the *Standard stock solution* to a 50-mL polypropylene, screw-cap centrifuge tube containing 5 mL of *Borate solution*. Add 5 mL of *Solution A*, and shake for 30 s. Allow to stand at room temperature for 25 min. Add 25 mL of methylene chloride, and shake vigorously for 1 min. Centrifuge for 5–10 min. Use a portion of the clear upper aqueous layer.

**Reagent blank:** Transfer 5.0 mL of *Diluent* to a 50-mL polypropylene, screw-cap centrifuge tube containing 5 mL of *Borate solution*. Add 5 mL of *Solution A*, and shake for 30 s. Allow to stand at room temperature for 25 min. Add 25 mL of methylene chloride, and shake vigorously for 1 min. Centrifuge for 5–10 min. Use a portion of the clear upper aqueous layer.

**Sample stock solution:** 0.1 mg/mL of Alendronate Sodium in *Diluent*

**Sample solution:** Transfer 5.0 mL of the *Sample stock solution* to a 50-mL polypropylene, screw-cap centrifuge tube containing 5 mL of *Borate solution*. Add 5 mL of *Solution A*, and shake for 30 s. Allow to stand at room temperature for 25 min. Add 25 mL of methylene chloride, and shake vigorously for 1 min. Centrifuge for 5–10 min. Use a portion of the clear upper aqueous layer.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 266 nm

**Column:** 4.1-mm × 25-cm; packing L21

**Column temperature:** 35°

**Flow rate:** 1.2 mL/min

**Injection volume:** 10 µL

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 1.5

**Relative standard deviation:** NMT 2.0% for replicate injections

## Analysis

**Samples:** *Standard solution*, *Reagent blank*, and *Sample solution*

Calculate the percentage of alendronate sodium ( $C_4H_{12}NNaO_7P_2$ ) in the portion of Alendronate Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak area from the *Sample solution*

$r_S$  = peak area from the *Standard solution*

$C_S$  = concentration of [USP Alendronate Sodium RS](#) in the *Standard stock solution* (mg/mL)

$C_U$  = concentration of Alendronate Sodium in the *Sample stock solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the dried basis

## IMPURITIES

### • ORGANIC IMPURITIES

**Buffer solution:** 2.94 g/L of sodium citrate dihydrate and 1.42 g/L of anhydrous dibasic sodium phosphate. Adjust with phosphoric acid to a pH of 8 and pass through a filter of 0.5-µm or finer pore size.

**Solution A:** Acetonitrile and *Buffer solution* (3:17)

**Solution B:** Acetonitrile and *Buffer solution* (7:3)

**Mobile phase:** See [Table 1](#).

**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	100	0
15	50	50
25	0	100
27	100	0
32	100	0

**Diluent and Borate solution:** Proceed as directed in the Assay.

**Solution C:** 4 mg/mL of 9-fluorenylmethyl chloroformate in acetonitrile. [NOTE—Prepare this solution fresh just before use.]

**Standard stock solution:** 0.6 mg/mL of [USP Alendronate Sodium RS](#) in *Diluent*

**Standard solution A:** Transfer 5.0 mL of the *Standard stock solution* to a 50-mL polypropylene, screw-cap centrifuge tube containing 5 mL of *Borate solution*. Add 5 mL of acetonitrile and 5 mL of *Solution C*, and shake for 45 s. Allow to stand at room temperature for 30 min. Add 20 mL of methylene chloride, and shake vigorously for 1 min. Centrifuge for 5–10 min, and use a portion of the clear upper aqueous layer.

**Standard solution B:** 0.6 µg/mL of [USP Alendronate Sodium RS](#) in *Diluent* from *Standard stock solution*. Transfer 5 mL of this diluted solution (0.6 µg/mL) to a 50-mL polypropylene, screw-cap centrifuge tube containing 5 mL of *Borate solution*. Add 5 mL of acetonitrile and 5 mL of *Solution C*, and shake for 45 s. Allow to stand at room temperature for 30 min. Add 20 mL of methylene chloride, and shake vigorously for 1 min. Centrifuge for 5–10 min, and use a portion of the clear upper aqueous layer.

**Reagent blank:** Transfer 5.0 mL of *Diluent* to a 50-mL polypropylene, screw-cap centrifuge tube containing 5 mL of *Borate solution*. Add 5 mL of acetonitrile and 5 mL of *Solution C*, and shake for 45 s. Allow to stand at room temperature for 30 min. Add 20 mL of methylene chloride, and shake vigorously for 1 min. Centrifuge for 5–10 min, and use a portion of the clear upper aqueous layer.

**Sample stock solution:** 0.6 mg/mL of Alendronate Sodium in *Diluent*

**Sample solution:** Transfer 5.0 mL of *Sample stock solution* to a 50-mL polypropylene, screw-cap centrifuge tube containing 5 mL of *Borate solution*. Add 5 mL of acetonitrile and 5 mL of *Solution C*, and shake for 45 s. Allow to stand at room temperature for 30 min. Add 20 mL of methylene chloride, and shake vigorously for 1 min. Centrifuge for 5–10 min, and use a portion of the clear upper aqueous layer.

## Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 266 nm

**Column:** 4.1-mm × 25-cm; packing L21

**Column temperature:** 45°

**Flow rate:** 1.8 mL/min

**Injection volume:** 20 µL

**System suitability**

**Samples:** *Standard solution A* and *Standard solution B*

**Suitability requirements**

**Tailing factor:** NMT 2.0 for the main peak, *Standard solution A*

**Signal-to-noise ratio:** NLT 3 for the main peak, *Standard solution B*

**Analysis**

**Samples:** *Reagent blank* and *Sample solution*

[NOTE—Disregard any peak corresponding to those obtained from the *Reagent blank*.]

Calculate the percentage of each impurity in the portion of Alendronate Sodium taken:

$$\text{Result} = (r_U/r_T) \times 100$$

$r_U$  = peak area of each impurity

$r_T$  = sum of all impurity peaks and the main peak

**Acceptance criteria**

**Individual impurities:** NMT 0.1%

**Total impurities:** NMT 0.5%

**SPECIFIC TESTS**

- [Loss on Drying \(731\)](#)

**Sample:** Dry at a pressure of NMT 5 mm of mercury at 140° to constant weight.

**Acceptance criteria:** 16.1%–17.1%

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, and store at room temperature.
- [USP REFERENCE STANDARDS \(11\)](#)  
[USP Alendronate Sodium RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ALENDRONATE SODIUM	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 41(2)

**Current DocID:** GUID-4A9200C8-C456-4486-A155-51E266B6C0C1\_4\_en-US

**DOI:** [https://doi.org/10.31003/USPNE\\_M1324\\_04\\_01](https://doi.org/10.31003/USPNE_M1324_04_01)

**DOI ref:** [qpe3y](#)